The Central Drugs Standard Control Organisation (CDSCO) will conduct testing, inspection and auditing of cough syrup manufacturers.
'Initiatives such as the Young Professionals Scheme also offer young graduates the chance to live and work in the UK after gaining experience.'
The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
Now a multi-dimensional rate structure has been created for CGHS cardholders in all categories based on four different parameters, with semi-private rooms forming the base for package rates.
Health ministry advisory urges rational use of cough syrups in children after 11 deaths in Madhya Pradesh and Rajasthan.
The Delhi government's directive banning sending of genetic samples outside the city for advanced prenatal tests has hit opposition, with diagnostic players in the capital citing operational difficulties in complying with the order. This comes after the Annual Report on Registration of Births and Deaths in Delhi 2024 indicated that the city's sex ratio at birth (SRB) had dropped to 920 girls per 1,000 boys in 2024, down from 922 in 2023.
Amid controversy over USPresident Donald Trump's comments linking the use of Tylenol and other related paracetamol products by pregnant women to autism in children, experts and industry executives say that since India's export of the drug to the US is less, it will hardly affect the country's pharma exports to America.
Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of the human insulin pen market by the end of this year and creates an opportunity estimated to be worth Rs 600-800 crore in the domestic market. Some self-use disposable pens are pre-filled with insulin and others can be reused with new cartridges.
'The directives to enhance last-mile funding, consider revival funds, and systemic reforms across the sector are expected to revive stalled projects, improve accountability, and accelerate the delivery of affordable and mid-income housing.'
'Even if tariffs are reduced, non-tariff may still remain a challenge.'
Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.
'A deal will only be possible if India stops buying Russian oil -- but even then, New Delhi must not compromise its core red lines.'
'Our endeavour will be that we identify these products, put them in the public domain so that the manufacturers can look at them and give a boost to Make in India.'
'Despite assurance from China, none of the companies have received supplies from Chinese sellers.'
'While the concept was introduced globally over four decades ago, branded residences have taken off now in India.'
'There is definitely tepid demand because of the (reciprocal tariff) uncertainty.'
With the rise in elderly population and increasing interest around the segment by developers, the senior living industry is poised to reach a market size of $8 billion by 2030 from the current $1.8 to $2 billion, according to a report by Association of Senior Living in India (ASLI) and JLL.
Any potential tariffs on pharmaceutical imports into the US are unlikely to impact the credit profiles of Indian firms except for a short-term pricing blip, according to a report by India Ratings and Research (Ind-Ra). The report stated that the US generics market contributes around 35 per cent to the total revenue of the leading Indian pharma firms.
The deal fell through over unresolved disagreements over contentious issues, mainly on agriculture and automotive sector tariffs.
India's goods exports rebounded in July after two months of contraction, with outbound shipments rising 7.3 per cent to $37.24 billion, led by a surge in exports to the United States before the country's reciprocal tariff kicked in and bolstered by a recovery in exports to other key markets.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances